Haemostatic function in patients undergoing coronary artery bypass grafting peroperative perturbations and relations to saphenous vein graft closure

Thrombosis Research

Volumn 98, Issue 1, 2000, Pages 39-49

  Moor, Elisabeth ^a   Blombäck, Margareta ^a   Silveira, Angela ^a   Wiman, Björn ^a   Cederlund, Kerstin ^a   Bergstrand, Lott ^a   Ivert, Torbjörn ^a   Rydén, Lars ^a   Hamsten, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bypass surgery; Coagulation; Fibrinolysis; Haemostatic function; Vein graft occlusion

Indexed keywords

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CORONARY ARTERY BYPASS GRAFT; FIBRINOLYSIS; GRAFT OCCLUSION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT;

ADULT; AGED; CORONARY ARTERY BYPASS; CORONARY DISEASE; GRAFT REJECTION; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SAPHENOUS VEIN;

EID: 0343820053     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00221-2     Document Type: Article

References (38)

1. Pfisterer M., Burkart F., Jockers G., Meyer B., Regenass S., Burckhardt D., Schmitt H.E., Muller-Brand J., Skarvan K., Stulz P. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet. 2:1989;1-7.
2. Guiteras P., Altimiras J., Aris A., Augé J.M., Bassons T., Bonal J., Caralps J.M., Castellarnau C., Crexells C., Masotti M., Oriol A., Padro J.M., Ruttlant M. Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole. A randomized, double-blind placebo-controlled trial Eur Heart J. 10:1989;159-167.
3. Goldman S., Copeland J., Moritz T., Henderson W., Zadina K., Ovitt T., Doherty J., Read R., Chesler E., Sako Y., Lancaster L., Emery R., Sharma G.V.R.K., Josa M., Pacold I., Montoya A., Parikh D., Sethi G., Holt J., Kirklin J., Shabetai R., Moores W., Aldridge J., Masud Z., DeMots H., Floten S., Haakenson C., Harker L.A. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of the Veterans Administration Cooperative Study. Circulation. 80:1989;1190-1197.
4. Sanz G., Pajaron A., Alegria E., Coello I., Cardona M., Fournier J.A., Goméz-Recio M., Ruano J., Hidalgo R., Medina A., Oller G., Colman T., Malpartida F., Xavier B. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Espanol para el Seguimiento del Injerto Coronario (GESIC). Circulation. 82:1990;765-773.
5. Loop F.D., Lytle B.W., Cosgrove D.M., Stewart R.W., Goormastic M., Williams G.W., Golding L.A.R., Gill C.C., Taylor P.C., Sheldon W.C., Proudfit W.L. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 314:1986;1-6.
6. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med. 332:1995;677-678.
7. Moor E., Hamsten A., Blombäck M., Herzfeld I., Wiman B., Rydén L. Hemostatic factors and inhibitors and coronary artery bypass grafting. Preoperative alterations and relations to graft occlusion Thromb Haemost. 72:1994;335-342.
8. Arnesen H., Semb G., Hol R., Karlsen H. Fibrinolytic capacity after venous stasis in patients undergoing aorto-coronary by-pass surgery. Relation to shunt occlusion. Scand J Haematol. 30(Suppl 39):1983;43-46.
9. Eritsland J., Arnesen H., Seljeflot I., Abdelnoor M., Grønseth K., Berg K., Malinov M.R. Influence of serum lipoprotein(a) and homcyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol. 74:1994;1099-1102.
10. Eritsland J., Gjønnes G., Sandset P.M., Seljeflot I., Arnesen H. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res. 79:1995;223-226.
11. Björk V.O., Ekeström S., Henze A., Ivert T., Landou C. Early and late patency of aortocoronary vein grafts. Scand J Thor Cardiovasc Surg. 15:1981;11-21.
12. Eritsland J., Arnesen H., Fjeld N.B., Grønseth K., Abdelnoor M. Risk factors for graft occlusion after coronary artery bypass grafting. Scand J Thor Cardiovasc Surg. 29:1995;63-69.
13. Crosby I.K., Wellons H.A. Jr., Taylor G.J., Maffeo C.J., Beller G.A., Muller W.H. Jr. Critical analysis of the preoperative and operative predictors of aortocoronary bypass patency. Ann Surg. 193:1981;743-751.
14. Cataldo G., Braga M., Pirotta N., Lavezzari M., Rovelli F., Marubini E. Factors influencing 1-year patency of coronary artery saphenous vein grafts. Circulation. 88(part 2):1993;1193-1198.
15. Moor E., Silveira A., van't Hooft F., Tornvall P., Blombäck M., Wiman B., Rydén L., Hamsten A. Coagulation factor V (Arg506->Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting. Thromb Haemost. 80:1998;220-224.
16. Vermylen C., de Vreker R.A., Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerisation time (FPT test). Clin Chim Acta. 8:1963;418-424.
17. Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 81:1993;734-744.
18. Silveira A., Green F., Karpe F., Blombäck M., Humphries S., Hamsten A. Elevated levels of factor VII activity in the postprandial state. Effect of the factor VII Arg-Gln polymorphism Thromb Haemost. 72:1994;734-739.
19. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 59:1988;101-106.
20. Malm J., Laurell M., Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 68:1988;437-443.
21. Silveira A.M.V., Yamamoto T., Adamson L., Hessel B., Blombäck B. Application of an enzyme-linked immunosorbent assay (ELISA) to von Willebrand factor (vWF) and its derivatives. Thromb Res. 43:1986;91-102.
22. Chmielewska J., Wiman B. Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. Clin Chem. 32:1986;482-485.
23. Ødegaard O.R., Try K., Andersson T.R. Protein C. An automated activity assay Haemostasis. 17:1987;109-113.
24. Wiman B., Rånby M. Determination of soluble fibrin in plasma by rapid and quantitative spectrophotometric assay. Thromb Haemost. 55:1986;189-193.
25. Fink P.C., Römer M., Haeckel R., Fateh-Moghadam A., Delanghe J., Gressner A.M., Dubs R.W. Measurement of proteins with the Behring Nephelometer. A multicentre evaluation. J Clin Chem Clin Biochem. 27:1989;261-276.
26. Carlson K. Lipoprotein fractionation. J Clin Path. 26(Suppl 5):1973;32-37.
27. Dahlén G., Guyton J.R., Attar M., Farmer J.A., Kautz J.A., Gotto A.M. Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:1986;758-765.
28. Kirk R.E. Experimental design. Procedures for the behavioral sciences:1995;Brooks/Cole Publishing Company, Pacific Grove, CA, USA.
29. Hosmer D.W., Lemeshow S. Applied logistic regression. 1989;John Wiley and Sons Inc, New York.
30. Juhan-Vague I, Alessi M-C, Declerck PJ. Pathophysiology of fibrinolysis. In: Lijnen HR, Collen D, editors. Fibrinolysis. Bailliere's Clinical Haematology 1995;8:329-43.
31. Cox J.L., Chiasson D.A., Gotlieb A.I. Stranger in a strange land. The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries Prog Cardiovasc Dis. 34:1991;45-68.
32. Paramo J.A., Alfaro M.J., Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor - Relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemost. 54:1985;713-716.
33. Eriksson B.I., Eriksson E., Gyzander E., Teger-Nilsson A.-C., Risberg B. Thrombosis after hip replacement. Relationship to the fibrinolytic system. Acta Orthop Scand. 60:1989;159-163.
34. Kauhanen P., Sirén V., Carpén O., Vaheri A., Lepäntalo M., Lassila R. Plasminogen activator inhibitor-1 in neointima of vein grafts. Its role in reduced fibrinolytic potential and graft failure Circulation. 96:1997;1783-1789.
35. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 268:1993;10739-10745.
36. Eggesbø J.B., Hjermann I., Høstmark A.T., Joø G.B., Kierulf P. Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A, and PAI-1 levels in persons with high or low levels of HDL-lipoprotein. Thromb Res. 70:1993;161-171.
37. Mannucci L., Gerometta P.S., Mussoni L., Antona C., Parolari A., Salvi L., Biglioli P., Tremoli E. One-month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Thromb Haemost. 73:1995;356-361.
38. Nilsen D.W.T., Almdahl S.M., Svensson B., Vaage J., Rasmussen K., Østerud B. Lipopolysaccharide induced monocyte thromboplastin synthesis and coagulation responses in patients undergoing coronary bypass surgery after preoperative supplementation with n-3 fatty acids. Thromb Haemost. 70:1993;900-902.